Varmus's Joint BSA-NCAB Meeting Remarks - June 23, 2014.NCI has received some relief from sequestration, and the budget cuts will be adjusted proportionally, Director Harold Varmus said at the joint meeting of the National Cancer Advisory Board and the Board of Scientific Advisors June 23.
ODAC member Brent Logan, professor of biostatistics at the Medical College of Wisconsin, said he didn't have confidence in the PFS advantage seen in Study 19.
Some of the questions that landed the AstraZeneca drug Olaparib (lynparza) before the FDA Oncologic Drugs Advisory Committee were classic:
BAYER PHARMA AG and arGEN-X announced a collaboration to develop therapeutic antibodies.
ELI LILLY AND COMPANY and Qiagen N.V. announced a plan to co-develop universal and modular assay panels for the simultaneous analysis of DNA and RNA biomarkers targeting multiple cellular pathways involved in common cancer types.
DANA-FARBER CANCER INSTITUTE and Trovagene Inc. entered into a clinical collaboration to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients.
YESHIVA UNIVERSITY and Montefiore Health System agreed to have Montefiore assume greater responsibility for the day-to-day operations and financial management of Albert Einstein College of Medicine, with Yeshiva remaining the degree-granting institution.
HIROMITSU OTA received the 2014 Ching Jer Chern Memorial Award from The Wistar Institute.
SANDEEP REDDY was named chief medical officer of Caris Life Sciences.
PATRICIA LORUSSO was named associate director of innovative medicine at Yale Cancer Center. She will take the job in August, and will also serve as a professor of medicine.
